Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Donald Catanzaro

Concepts (143)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Mycobacterium tuberculosis
29
2025
266
4.270
Why?
Tuberculosis, Multidrug-Resistant
14
2023
40
3.190
Why?
Antitubercular Agents
19
2023
102
2.530
Why?
Tuberculosis
12
2025
130
2.200
Why?
Drug Resistance, Multiple, Bacterial
13
2023
64
1.390
Why?
Microbial Sensitivity Tests
16
2023
269
1.280
Why?
Extensively Drug-Resistant Tuberculosis
8
2023
12
1.090
Why?
Latent Tuberculosis
4
2024
9
0.840
Why?
Molecular Diagnostic Techniques
7
2025
33
0.780
Why?
Tuberculosis, Pulmonary
6
2024
105
0.730
Why?
Mutation
10
2020
1280
0.610
Why?
Bacterial Proteins
9
2023
367
0.570
Why?
Population Dynamics
1
2016
17
0.550
Why?
Fluoroquinolones
5
2023
24
0.520
Why?
Drug Resistance, Bacterial
4
2017
72
0.510
Why?
Sequence Analysis, DNA
8
2019
226
0.450
Why?
DNA, Bacterial
7
2025
186
0.420
Why?
Isoniazid
6
2023
33
0.390
Why?
Humans
37
2025
50503
0.320
Why?
Sputum
6
2025
65
0.310
Why?
Air Pollution
2
2019
46
0.300
Why?
Air Pollutants
2
2019
64
0.290
Why?
India
6
2018
53
0.290
Why?
Sensitivity and Specificity
8
2025
859
0.280
Why?
Adult
15
2025
13577
0.270
Why?
Middle Aged
13
2025
12611
0.260
Why?
Young Adult
10
2025
4102
0.250
Why?
Moldova
7
2024
11
0.250
Why?
California
3
2019
86
0.240
Why?
Prospective Studies
8
2025
2378
0.220
Why?
Mycobacterium Infections, Nontuberculous
1
2022
19
0.200
Why?
High-Throughput Nucleotide Sequencing
3
2019
169
0.200
Why?
Tuberculosis, Lymph Node
1
2022
2
0.200
Why?
Lung Diseases
1
2023
94
0.200
Why?
Directly Observed Therapy
2
2020
7
0.200
Why?
Male
14
2025
25907
0.190
Why?
Disease Progression
1
2024
829
0.190
Why?
South Africa
6
2018
22
0.190
Why?
Aged
9
2025
9741
0.190
Why?
Pneumonia
1
2022
116
0.190
Why?
Female
14
2025
27081
0.190
Why?
Laboratories
1
2020
19
0.180
Why?
Residence Characteristics
2
2019
150
0.180
Why?
Adolescent
9
2025
6443
0.170
Why?
Trees
1
2019
17
0.170
Why?
Urban Health Services
1
2019
21
0.170
Why?
Bacteriological Techniques
2
2017
41
0.170
Why?
Health Care Costs
2
2018
167
0.160
Why?
Transcriptome
1
2021
313
0.160
Why?
DNA Gyrase
2
2015
4
0.150
Why?
Catalase
2
2015
67
0.150
Why?
Child
8
2025
6906
0.150
Why?
HIV Infections
1
2022
352
0.150
Why?
Vehicle Emissions
1
2017
9
0.150
Why?
Kanamycin
4
2023
6
0.150
Why?
ROC Curve
1
2017
226
0.130
Why?
Genotyping Techniques
1
2016
20
0.130
Why?
Specimen Handling
1
2016
55
0.130
Why?
Cohort Studies
2
2017
1452
0.130
Why?
Risk Factors
3
2024
3724
0.130
Why?
Rifampin
3
2023
59
0.120
Why?
Socioeconomic Factors
1
2016
591
0.110
Why?
Capreomycin
3
2023
4
0.110
Why?
Logistic Models
1
2016
900
0.110
Why?
Genotype
4
2017
533
0.110
Why?
Point Mutation
1
2013
62
0.110
Why?
Dose-Response Relationship, Drug
1
2017
1372
0.110
Why?
Prevalence
1
2016
971
0.110
Why?
Aged, 80 and over
5
2020
3226
0.110
Why?
Interferon-gamma
2
2024
177
0.100
Why?
Promoter Regions, Genetic
4
2016
465
0.100
Why?
Research Design
1
2014
353
0.100
Why?
Lung
1
2016
504
0.100
Why?
Cross-Sectional Studies
1
2016
1610
0.090
Why?
Risk Assessment
2
2017
1270
0.090
Why?
Lyme Disease
1
2011
32
0.090
Why?
Predictive Value of Tests
3
2022
930
0.090
Why?
Environment
1
2011
81
0.090
Why?
Oxidoreductases
3
2015
59
0.090
Why?
Anti-Bacterial Agents
2
2015
745
0.090
Why?
Polymorphism, Single Nucleotide
3
2019
475
0.080
Why?
Antigens, Bacterial
2
2024
51
0.080
Why?
Reproducibility of Results
3
2019
1197
0.080
Why?
Amikacin
2
2023
19
0.080
Why?
Phenotype
3
2015
739
0.070
Why?
Child, Preschool
3
2025
3942
0.070
Why?
Time Factors
3
2019
2935
0.060
Why?
Incidence
2
2024
1032
0.060
Why?
Cost-Benefit Analysis
2
2019
266
0.060
Why?
Pakistan
1
2025
17
0.060
Why?
Contact Tracing
1
2024
6
0.060
Why?
Philippines
2
2015
10
0.060
Why?
Point-of-Care Systems
1
2025
57
0.060
Why?
Epitopes, T-Lymphocyte
1
2024
25
0.060
Why?
Tuberculin Test
1
2023
8
0.050
Why?
Interferon-gamma Release Tests
1
2023
8
0.050
Why?
Peptides
1
2024
221
0.050
Why?
Mitochondrial Dynamics
1
2022
21
0.050
Why?
Kenya
1
2022
10
0.050
Why?
Pathology, Molecular
1
2022
22
0.050
Why?
Proteome
1
2024
169
0.050
Why?
England
1
2021
45
0.050
Why?
Tissue Array Analysis
1
2021
45
0.050
Why?
State Medicine
1
2021
14
0.050
Why?
San Francisco
1
2020
12
0.040
Why?
United States
2
2022
4955
0.040
Why?
New York City
1
2020
25
0.040
Why?
Ofloxacin
1
2019
7
0.040
Why?
Longitudinal Studies
1
2021
735
0.040
Why?
Costs and Cost Analysis
1
2018
90
0.040
Why?
Algorithms
1
2022
625
0.040
Why?
Video Recording
1
2018
79
0.040
Why?
Case-Control Studies
1
2021
1156
0.040
Why?
Pyrazinamide
1
2017
8
0.040
Why?
Medication Adherence
1
2018
129
0.030
Why?
DNA Mutational Analysis
1
2017
175
0.030
Why?
Kanamycin Resistance
1
2016
1
0.030
Why?
Molecular Typing
1
2016
10
0.030
Why?
Risk
1
2017
324
0.030
Why?
Gene Expression Profiling
1
2021
1025
0.030
Why?
Genes, Bacterial
1
2016
58
0.030
Why?
Infant
1
2025
3628
0.030
Why?
Bacterial Load
1
2016
12
0.030
Why?
Proportional Hazards Models
1
2017
415
0.030
Why?
Reference Standards
1
2016
52
0.030
Why?
Calibration
1
2016
57
0.030
Why?
Nucleic Acid Hybridization
1
2016
55
0.030
Why?
Environmental Exposure
1
2017
200
0.030
Why?
Pharmaceutical Preparations
1
2016
76
0.030
Why?
Survival Analysis
1
2017
661
0.030
Why?
Genetic Loci
1
2015
45
0.030
Why?
Gene Frequency
1
2015
97
0.030
Why?
Meta-Analysis as Topic
1
2015
38
0.030
Why?
DNA-Directed RNA Polymerases
1
2014
14
0.030
Why?
Clinical Protocols
1
2014
110
0.030
Why?
Time-to-Treatment
1
2014
73
0.030
Why?
Pilot Projects
1
2016
698
0.030
Why?
Base Sequence
1
2014
639
0.030
Why?
Acetyltransferases
1
2012
19
0.020
Why?
Methyltransferases
1
2012
30
0.020
Why?
Treatment Outcome
1
2022
5283
0.020
Why?
Maryland
1
2011
32
0.020
Why?
Models, Biological
1
2011
716
0.020
Why?
Catanzaro's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Similar People Expand Description
_